Immunome, Inc. cash flow to debt ratio of -4.95K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Immunome, Inc.'s free cash flow has decreased 22.09% from $-164.30M last year to $-200.60M, signaling decreasing performance

Immunome, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Immunome, Inc.'s debt has decreased relative to shareholder equity from 0.03 last year to 0.01 today, signaling strengthened financials

Immunome, Inc. has a net cash position, so leverage is healthy.

Immunome, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Immunome, Inc.'s profit margin has decreased (72.63%) in the last year from -3.24K% to -5.59K%, signaling decreasing performance

Immunome, Inc.'s short-term assets of $660.78M exceed its short-term liabilities of $44.99M

Immunome, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Immunome, Inc.'s return on equity of -51.15%, is lower than 15.00%, indicating bad performance

Immunome, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Immunome, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Immunome, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Immunome, Inc. has negative free cash flow, indicating cash burn

Immunome, Inc.'s yearly earnings has increased -27.50% since last year from $-292.96M to $-212.39M, signaling increasing performance

Immunome, Inc.'s yearly revenue has decreased 23.23% since last year from $9.04M to $6.94M, signaling decreasing performance

ROIC -40.31% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Immunome, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Immunome, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Immunome, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Immunome, Inc. is overvalued relative to its fair value price of 3.84 based on Discounted Cash Flow model

Immunome, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Immunome, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Immunome, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Immunome, Inc. has insufficient data to evaluate this check.

Immunome, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Immunome, Inc. has a price-to-book ratio of 4.94x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Immunome, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue